Corrigendum to ‘Mechanisms of paracrine cardioprotection by cord blood mesenchymal stromal cells’

Andreas Matthaeus Badera, Andreja Brodarac, Kristin Klosea, Karen Biebackb,
Yeong-Hoon Choic, Andreas Kurtza and Christof Stamm*–
d,*
a Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Berlin, Germany
b Institute of Transfusion Medicine and Immunology, Mannheim, Germany
c Heart Center, University of Cologne, Cologne, Germany
d Deutsches Herzzentrum Berlin, Berlin, Germany

* Corresponding author. Deutsches Herzzentrum Berlin, Augustenburger Platz 1, 13353 Berlin, Germany. Tel: +49-30-45932109; fax: +49-30-45932100;
e-mail: stamm@dhzb.de (C. Stamm).

The authors regret that an error appeared in the above article.

When reading the manufacturer’s certificate of the Luminex cytokine/growth factor screening assay, a comma (thousand separator) was mistaken for a decimal separator. Hence, the analyte concentrations given in the article as pg/ml are in fact ng/ml. The paragraph of the subsection ‘Growth factors and cytokines in conditioned medium’ under RESULTS should read:

In fibroblast-conditioned medium, the total protein content was 26 ± 10% lower than in CBMSC medium (CBMSC 27 ± 2 vs fibroblasts 20 ± 2 µg/ml, P < 0.05). The concentrations of selected growth factors and cytokines are shown in Fig. 2. The concentrations of VEGF (CBMSC 6.0 ± 0.9; fibroblast 4.9 ± 0.7 ng/ml), EGF (CBMSC 0.83 ± 0.09; fibroblast 0.65 ± 0.06 ng/ml), and Angiopoetin-2 (CBMSC 0.44 ± 0.04; fibroblast 0.49 ± 0.06 ng/ml) were similar, CBMSC medium contained more HGF (CBMSC 0.36 ± 0.05 vs fibroblast 0.04 ± 0.01 ng/ml, P < 0.001), and fibroblast medium more bFGF (CBMSC 0.08 ± 0.02 vs fibroblast 0.59 ± 0.14 ng/ml, P < 0.05) and IL-6 (CBMSC 0.15 ± 0.03 vs fibroblast 5.8 ± 1.0 ng/ml, P < 0.001). IL-10 and TNFα were not detectable in either medium.

In addition, the Y-axis in Figure 2 should indicate ng/ml rather than pg/ml.

The DOI of original article: 10.1093/ezu326

Corrigendum to ‘Second primary non-small-cell lung cancer: implications of the new adenocarcinoma classification in the challenging decision of the best surgical strategy’

Lococo Filippo*, Alfredo Cesariob, Giovanni Leuzzi1 and Giovanni Apoloneb

* Unit of Thoracic Surgery, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
b IRCCS San Raffaele Pisana, Rome, Italy
c Department of General Thoracic Surgery, Catholic University of Sacred Heart, Rome, Italy

* Corresponding author. Unit of Thoracic Surgery, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy. Tel: +39-0697612152/+39-3294131202;
e-mail: filippo_lococo@yahoo.it (L. Filippo).

Giovanni Leuzzi is no longer at the above-mentioned institution. His present address is: Department of Surgical Oncology, Thoracic Surgery Unit, Regina Elena National Cancer Institute, Rome, Italy.
Alfredo Cesario’s correct affiliation is: Scientific Direction, IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Italy.

The DOI of original article: 10.1093/ezu438